Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4
Public ClinicalTrials.gov record NCT03556592. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multi Centre Drug-drug Interaction Trial to Investigate the Effects of Tralokinumab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Subjects With Moderate-to-severe Atopic Dermatitis
Study identification
- NCT ID
- NCT03556592
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- LEO Pharma
- Industry
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Interventions
- Caffeine Drug
- Metoprolol Drug
- Midazolam Hydrochloride Drug
- Omeprazole Drug
- Tralokinumab Drug
- Warfarin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 12, 2018
- Primary completion
- Mar 15, 2020
- Completion
- Jun 19, 2020
- Last update posted
- Feb 23, 2025
2018 – 2020
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| LEO Pharma Investigational Site | Little Rock | Arkansas | 72212 | — |
| LEO Pharma Investigational Site | Rogers | Arkansas | 72758 | — |
| LEO Pharma Investigational Site | San Diego | California | 92119 | — |
| LEO Pharma Investigational Site | Doral | Florida | 33122 | — |
| LEO Pharma Investigational Site | Miami | Florida | 33015 | — |
| LEO Pharma Investigational Site | Miami | Florida | 33144 | — |
| LEO Pharma Investigational Site | Quincy | Massachusetts | 02169 | — |
| LEO Pharma Investigational Site | Spartanburg | South Carolina | 29303 | — |
| LEO Pharma Investigational Site | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03556592, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 23, 2025 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03556592 live on ClinicalTrials.gov.